Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01609803 · ClinicalTrials.gov registry record
Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma
A clinical trial, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 99
- Enrollment target
NCT01609803: Completed study, sponsored by Children's Oncology Group.
NCT01609803 is a clinical trial that has completed, run by Children's Oncology Group. The registered enrollment target is 99 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01609803 has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 99 participants
- Enrollment target
Study Summary
This research trial studies protein expression in tissue samples from younger patients with rhabdomyosarcoma. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
Primary Outcome
Fisher's exact test will be used. For a contingency table other than 2 x 2, the Freeman-Halton test (an extension of Fisher's exact test) will be applied instead.
Interventions
- OTHER laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-05 |
What the finished NCT01609803 record still lists
NCT01609803 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 99 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which laboratory biomarker analysis is the first listed.
NCT01609803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01609803 about?
NCT01609803 is a clinical study titled "Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma". This research trial studies protein expression in tissue samples from younger patients with rhabdomyosarcoma. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help...
What is the current status of trial NCT01609803?
This trial is currently completed. The enrollment target is 99 participants. The study started on 2012-06. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01609803?
The interventions under investigation include: laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT01609803?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia